new ceo and board 'business model', page-64

Perhaps she didn't step up as would be expected of a senior executive when Esra hit the fan - Harry coming back full time but not as CEO and who has certainly stepped up - possibly its a game of musical chairs with only so many senior roles/salaries to go around. As for who will run phase 2/3 I think we will find our new ceo's credentials are heavily weighted towards someone who is able to prove their ability to push a drug through trials to commericialbility......rather than being a pure business type from an unrelated industry......I get the feeling this new CEO will be very hands on - something as it turns out our last CEO wasn't (wasn't at the negotiation table or the lab) ---unless you count the hands in the till!!!